
Should You Get Genetic Testing for Pancreatic Cancer?
Genetic testing for pancreatic cancer isn't just for patients—NCCN urges it for all who are diagnosed, and carriers may start screening years earlier.
Sameer Patel is the founder and editor of My Medicine Advisor. He is not a doctor or medical professional — before starting this site he worked in banking, and he now researches and edits health information full-time.
He started My Medicine Advisor to make clear, well-sourced health information freely available to anyone. Every article is researched from recognised authorities such as the WHO, CDC, NIH, and NICE, drafted with the help of AI tools, and edited by hand, with sources linked so readers can check them. The calculators on the site use established, published formulas, each one named so you can look it up yourself.
My Medicine Advisor is currently a one-person operation with no clinical review panel, and the site is open about that. If you're a qualified clinician or researcher interested in reviewing content, Sameer would genuinely like to hear from you via the contact page.

Genetic testing for pancreatic cancer isn't just for patients—NCCN urges it for all who are diagnosed, and carriers may start screening years earlier.

Hereditary pancreatic cancer is behind about 1 in 10 cases. Knowing which genes—BRCA2, CDKN2A—raise risk helps you and your family decide on testing.

What causes pancreatic cancer is rarely one thing — but smoking accounts for about 1 in 4 cases, and the biggest risks are often ones you can change.

Pancreatic cancer pain often needs more than pills. A celiac plexus block can ease it — but it won't extend survival. Here's what each option really does.

Pancreatic cancer can block the gut two ways—at the stomach's outlet or lower in the bowel. Know the signs, the red flags, and what eases it.

Pancreatic cancer blood clots affect about 1 in 5 patients—the highest rate of any cancer. Here's why they happen, the warning signs, and when to act.

Pancreatic cancer clinical trials increasingly target KRAS — found in over 90% of tumors — so biomarker testing can open doors to new studies.

A pancreatic cancer mRNA vaccine is showing early promise in trials, but it is not yet approved. Here is what the research shows — and doesn't.

KRAS pancreatic cancer treatment just reached a turning point: drugs targeting the gene behind 90% of these tumors are now showing real benefit in trials.

Pancreatic cancer chemo side effects vary by regimen—and fatigue affects over 80% of people on chemo. Here's what's common, what's serious, and what helps.